Adagene Inc. (ADAG)
ADAG Stock Price Chart
Explore Adagene Inc. interactive price chart. Choose custom timeframes to analyze ADAG price movements and trends.
ADAG Company Profile
Discover essential business fundamentals and corporate details for Adagene Inc. (ADAG) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 Feb 2021
Employees
138.00
Website
https://www.adagene.comCEO
Peter P. Luo
Description
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
ADAG Financial Timeline
Browse a chronological timeline of Adagene Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 23 Mar 2026
Earnings released on 12 Aug 2025
EPS came in at -$0.23 surpassing the estimated -$0.32 by +28.13%.
Earnings released on 24 Mar 2025
EPS came in at -$0.55 falling short of the estimated -$0.33 by -67.69%, while revenue for the quarter reached $103.20K .
Earnings released on 25 Jul 2024
EPS came in at -$0.19 surpassing the estimated -$0.41 by +53.03%.
Earnings released on 31 Mar 2024
EPS came in at -$0.19 .
Earnings released on 29 Mar 2024
EPS came in at -$0.17 surpassing the estimated -$0.42 by +59.76%, while revenue for the quarter reached $407.87K .
Earnings released on 30 Sept 2023
EPS came in at -$0.17 , while revenue for the quarter reached $407.87K .
Earnings released on 31 Aug 2023
EPS came in at -$0.05 surpassing the estimated -$0.38 by +87.62%, while revenue for the quarter reached $8.65M .
Earnings released on 31 Mar 2023
EPS came in at -$0.05 , while revenue for the quarter reached $8.65M .
Earnings released on 28 Mar 2023
EPS came in at -$1.55 falling short of the estimated -$0.40 by -287.50%, while revenue for the quarter reached $2.68M , missing expectations by -72.99%.
Earnings released on 30 Sept 2022
EPS came in at -$0.38 , while revenue for the quarter reached $2.68M .
Earnings released on 30 Aug 2022
EPS came in at -$1.09 falling short of the estimated -$0.65 by -68.01%, while revenue for the quarter reached $3.92M , missing expectations by -77.58%.
Earnings released on 30 Sept 2021
EPS came in at -$0.41 , while revenue for the quarter reached $4.41M .
Earnings released on 26 Aug 2021
EPS came in at -$1.02 falling short of the estimated -$0.39 by -161.89%, while revenue for the quarter reached $1.36M .
Earnings released on 30 Sept 2020
EPS came in at -$0.33 .
ADAG Stock Performance
Access detailed ADAG performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.